Novartis acquires Anthos' abelacimab for $925M upfront and up to $3.1B total, marking CEO Bill Meury's second major exit and ...

Leaked Pfizer Phase 1 trial shows mevrometostat plus Xtandi reduced prostate cancer progression risk by 49%. Data sparked ...

Pli­ant Ther­a­peu­tics has slammed the brakes on en­roll­ment and dos­ing in a mid-stage study of its lung dis­ease ...

Novo Nordisk hit back at telehealth company Hims’ controversial Super Bowl commercial touting cheaper versions of brand-name ...

Roche's $8 billion InterMune acquisition, disclosed a decade ago, is now being handed to a specialty pharmaceutical company.

Twenty-two state attorneys general sued the Trump administration on Monday in a bid to halt a new cap on indirect costs for ...

Vertex chief operating officer Stuart Arbuckle plans to retire in July, the company announced Monday afternoon. He will be ...

Eli Lilly is betting up to $630 million on an experimental MASH treatment from a South Korean biotech. The pharma giant ...

Several brand-name drugmakers believe they will withstand any drug pricing impacts from President Donald Trump’s tariffs — ...

Boehringer Ingelheim said its experimental treatment for a chronic lung disease succeeded in a pivotal study, and it's taking ...

German pharma company Merck KGaA confirmed that it is in talks to acquire SpringWorks Therapeutics, though a deal has yet to be announced.

Roivant ends namilumab program, Bio-Thera partners on golimumab biosimilar, Caliway advances fat treatment, Orca Bio's T cell success, funding for Alterity & Ascentage ...